Closing the Gap: Why Patient Perspectives Predict Survival Better Than Clinician Ratings in Sclerotic cGVHD
Posted inDermatology news Oncology Transplantation

Closing the Gap: Why Patient Perspectives Predict Survival Better Than Clinician Ratings in Sclerotic cGVHD

A multicenter study reveals significant discordance between clinician and patient assessments of skin cGVHD. While both correlate with survival, patient-reported outcomes are uniquely predictive of mortality in sclerotic disease, highlighting the need for integrated assessment models in clinical practice.
Beyond the Gut: Understanding the High Prevalence and Clinical Impact of JAK Inhibitor-Induced Acne in IBD
Posted inDermatology Gastroenterology news

Beyond the Gut: Understanding the High Prevalence and Clinical Impact of JAK Inhibitor-Induced Acne in IBD

An international multicenter study reveals that acne is a frequent adverse event in IBD patients treated with JAK inhibitors, particularly upadacitinib. The research highlights dose-dependency, significant psychosocial impacts, and the critical need for proactive dermatological management in clinical practice.
Aggressive Initial Management in Early Psoriatic Arthritis: Does Adding Golimumab to Methotrexate and Steroids Offer Superior Outcomes?
Posted inDermatology news Rheumatology

Aggressive Initial Management in Early Psoriatic Arthritis: Does Adding Golimumab to Methotrexate and Steroids Offer Superior Outcomes?

The GOLMePsA trial found no significant difference in disease activity at 24 weeks when adding golimumab to methotrexate and steroids for early PsA. However, the triple therapy significantly reduced the need for rescue corticosteroids, highlighting potential steroid-sparing benefits in early intervention.
Dose-Dependent Efficacy of Vixarelimab in Prurigo Nodularis: Targeting the OSMRβ Pathway for Itch and Lesion Resolution
Posted inDermatology news

Dose-Dependent Efficacy of Vixarelimab in Prurigo Nodularis: Targeting the OSMRβ Pathway for Itch and Lesion Resolution

This Phase 2b randomized clinical trial demonstrates that vixarelimab, a monoclonal antibody targeting OSMRβ, significantly reduces pruritus and promotes skin lesion clearance in patients with moderate-to-severe prurigo nodularis, offering a potent, dose-dependent therapeutic option with a favorable safety profile.
Causal Insights Into Hidradenitis Suppurativa: Mendelian Randomization Evidence Linking BMI, Inflammatory Bowel Disease, and Smoking
Posted inClinical Updates Dermatology Gastroenterology Internal Medicine news

Causal Insights Into Hidradenitis Suppurativa: Mendelian Randomization Evidence Linking BMI, Inflammatory Bowel Disease, and Smoking

Recent Mendelian randomization analyses demonstrate causal effects of increased BMI and inflammatory bowel disease on hidradenitis suppurativa risk, elucidating modifiable contributions beyond genetic correlations with psoriasis and systemic sclerosis.
Dutch Nationwide Registry Shows Large Health-System Burden and Early Progression Risk in Advanced Cutaneous Squamous Cell Carcinoma
Posted inDermatology news Oncology

Dutch Nationwide Registry Shows Large Health-System Burden and Early Progression Risk in Advanced Cutaneous Squamous Cell Carcinoma

The Dutch Keratinocyte Cancer Collaborative (DKCC) provides the first nationwide longitudinal real-world dataset of advanced cutaneous squamous cell carcinoma (CSCC), estimating that 8% of CSCC are locally advanced and demonstrating short median times to recurrence or metastasis, substantial resource needs, and meaningful proportions of untreated metastatic episodes.